Core Viewpoint - Clearmind Medicine Inc. is advancing its clinical trial for CMND-100, a non-hallucinogenic treatment for Alcohol Use Disorder (AUD), following positive results from previous cohorts [1][2][4]. Group 1: Clinical Trial Progress - The company is continuing participant enrollment for the third cohort of its FDA-approved Phase I/IIa clinical trial for CMND-100 [1]. - The second cohort's results showed continued safety and tolerability, leading to unanimous approval from the Data and Safety Monitoring Board (DSMB) to proceed with the next phase [2]. - The trial is a multinational, multicenter study aimed at evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100 in patients with moderate to severe AUD [3]. Group 2: Company Insights - Clearmind Medicine focuses on developing novel, non-hallucinogenic therapeutics derived from neuroplastogens to address significant health issues, including AUD [5]. - The company holds an intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents as necessary [6].

Core Viewpoint - Clearmind Medicine Inc. has received approval to continue its Phase I/IIa clinical trial for CMND-100, a non-hallucinogenic neuroplastogen aimed at treating Alcohol Use Disorder (AUD), based on positive safety results from the second cohort of participants [1][4]. Group 1: Clinical Trial Progress - The independent Data and Safety Monitoring Board (DSMB) completed a second interim review and recommended the continuation of the trial due to encouraging safety data from the second cohort [1][2]. - The second cohort involved six participants and demonstrated a favorable safety profile, reinforcing the results from the first cohort [2][3]. - The trial is designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100 in patients with moderate to severe AUD, conducted at leading medical centers [4]. Group 2: Dosage and Administration - In the second cohort, participants received a dose that was double that of the first cohort, with no serious adverse events reported, supporting the trial's progression to the third cohort with an 80 mg dose [3][4]. - The successful completion of treatment in the second cohort occurred shortly after DSMB clearance, indicating confidence in CMND-100's safety profile [4]. Group 3: Company Overview - Clearmind Medicine Inc. is focused on developing novel psychedelic-derived therapeutics to address under-treated health issues, including AUD [5]. - The company holds an intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents as needed [6].

Core Viewpoint - Clearmind Medicine Inc. announced positive safety topline results from the second cohort of its Phase I/IIa clinical trial for CMND-100, a non-hallucinogenic drug candidate aimed at treating Alcohol Use Disorder (AUD) [1][5]. Group 1: Clinical Trial Results - The second cohort of the trial involved six additional patients and confirmed the safety and tolerability profile established in the first cohort [2][3]. - No serious adverse events were reported, reinforcing the positive safety profile of CMND-100 [3][5]. - The trial is a multinational study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100 in patients with moderate to severe AUD [4]. Group 2: Company Overview - Clearmind is a clinical-stage biotech company focused on developing novel neuroplastogen-derived therapeutics for under-treated health issues, including AUD [1][6]. - The company holds a portfolio of nineteen patent families, with 31 granted patents, and aims to expand its intellectual property [7].

Core Insights - Clearmind Medicine Inc. has welcomed the inclusion of its proprietary compound MEAI in U.S. federal legislation for the first time, specifically in the Expanding Veterans' Access to Emerging Treatments Act of 2026 [1][3] Company Overview - Clearmind is a clinical-stage biotech company focused on developing novel neuroplastogen-derived therapeutics to address major under-treated health issues, including Alcohol Use Disorder [5] - The company has a portfolio of nineteen patent families, including 31 granted patents, and aims to expand its intellectual property [6] Legislative Context - The Expanding Veterans' Access to Emerging Treatments Act of 2026 directs the Department of Veterans Affairs to establish a research and treatment program for innovative therapies addressing unmet medical needs in veterans [2] - The bill explicitly includes therapies such as psilocybin, MDMA, MEAI, and others, which could lead to VA-supported clinical trials and extended access protocols for various conditions [3] Industry Impact - The inclusion of MEAI in the legislation is seen as a significant milestone, potentially transforming clinical treatment for veterans suffering from conditions like alcoholism and PTSD [4] - The recognition of MEAI highlights a growing support for innovative, evidence-based approaches to mental health treatment [4]

Core Insights - Clearmind Medicine Inc. has successfully completed treatment for all patients in the second cohort of its FDA-approved Phase I/IIa clinical trial for CMND-100, an oral drug candidate aimed at treating Alcohol Use Disorder (AUD) [1][2][3] Group 1: Clinical Trial Progress - The second cohort included six patients from leading clinical sites such as Johns Hopkins University and Tel Aviv Sourasky Medical Center, completing treatment as per protocol [2] - This milestone follows positive results from the first cohort, which indicated a favorable safety profile and preliminary efficacy, including reduced cravings and withdrawal symptoms [2][3] - The CEO of Clearmind Medicine expressed satisfaction with the progress and highlighted the strong interest in CMND-100 as a potential innovative therapy for AUD, a condition with significant unmet medical needs [3] Group 2: Company Overview - Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on developing novel psychedelic-derived therapeutics to address widespread health issues, including AUD [4] - The company holds an intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents as necessary [5] - Clearmind's shares are traded on Nasdaq under the symbol "CMND" and on the Frankfurt Stock Exchange under "CWY0" [5]

Core Viewpoint - Clearmind Medicine Inc. has regained compliance with Nasdaq's minimum bid price requirement after its shares closed at $1.00 or greater for 10 consecutive business days, resolving a previous non-compliance issue [1][3]. Company Overview - Clearmind Medicine Inc. is a clinical-stage biotech company focused on developing novel neuroplastogen-derived therapeutics aimed at addressing significant under-treated health issues, including alcohol use disorder [4]. - The company holds an intellectual property portfolio consisting of 19 patent families and 31 granted patents, with plans to seek additional patents and acquire more intellectual property as opportunities arise [5]. Compliance Update - On December 4, 2025, Nasdaq notified the company of its non-compliance with the minimum bid price requirement due to its shares trading below $1.00 for over 30 consecutive business days [2]. - Following a period of compliance, Nasdaq confirmed on December 30, 2025, that the company's shares had met the minimum bid price requirement, thus closing the matter [3].

Core Insights - Clearmind Medicine Inc. has made significant progress in 2025, particularly in advancing its lead candidate, CMND-100, for the treatment of Alcohol Use Disorder (AUD) [1][2] Clinical Trial Progress - Clearmind advanced its multinational Phase I/IIa clinical trial for CMND-100, with site activations at prestigious institutions such as Yale School of Medicine and Johns Hopkins University [3] - The company successfully initiated first-in-human dosing, completed treatment and enrollment for the first cohort, and reported positive top-line safety and tolerability results with no serious adverse events [3] - Enrollment and dosing for the second cohort were completed, accelerating the path toward further data readouts [3] Independent Safety Endorsement - Clearmind received unanimous approval from the Data and Safety Monitoring Board (DSMB) to continue the Phase I/IIa clinical trial following an interim review, reinforcing CMND-100's favorable safety profile [4] Global Footprint Expansion - The company strengthened its intellectual property portfolio with multiple international patent filings and publications targeting various health indications, including weight loss, obesity, and mental health disorders [5] Leadership Commentary - The CEO of Clearmind highlighted 2025 as a pivotal year for the company, emphasizing its transition into a clinical-stage entity and commitment to delivering transformative treatments for addictions and mental health challenges [6] Intellectual Property Portfolio - Clearmind's intellectual portfolio consists of nineteen patent families, including 31 granted patents, with plans to seek additional patents as warranted [8]

Core Insights - Clearmind Medicine Inc. has successfully completed patient enrollment for the second cohort in its FDA-approved Phase I/IIa clinical trial for CMND-100, an oral drug candidate aimed at treating Alcohol Use Disorder (AUD) [1][4] - The first cohort showed promising safety and efficacy results, indicating a favorable safety profile and preliminary signs of reduced cravings and withdrawal symptoms [2][4] - The rapid enrollment of the second cohort underscores the commitment of collaborating clinical centers to advance innovative treatments for AUD, a condition with limited effective options affecting millions globally [3][4] Company Overview - Clearmind is a clinical-stage biotech company focused on developing novel neuroplastogen-derived therapeutics to address under-treated health issues, particularly AUD [1][5] - The company holds an intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents and acquire more intellectual property [6] Clinical Trial Details - The multinational Phase I/IIa trial aims to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100 in patients with moderate to severe AUD, with dosing for the second cohort expected to start soon [4]

Core Insights - Clearmind Medicine Inc. has enrolled and dosed the first participant in its Phase I/IIa clinical trial for Alcohol Use Disorder (AUD) with its proprietary drug candidate CMND-100 at Hadassah-University Medical Center in Jerusalem, marking a significant milestone in the trial [1][2][3] Company Overview - Clearmind is a clinical-stage biotech company focused on developing novel neuroplastogen-derived therapeutics to address major under-treated health issues, including AUD [1][4] - The company aims to research and commercialize psychedelic-based compounds as regulated medicines, foods, or supplements [4] Clinical Trial Details - The trial at Hadassah-University Medical Center is led by Prof. Joseph Caraco and evaluates the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100 in AUD patients [2] - Recent positive results from the first cohort and a unanimous recommendation from the Data and Safety Monitoring Board support the continuation of the trial [2] Intellectual Property - Clearmind's intellectual portfolio includes nineteen patent families with 31 granted patents, and the company plans to seek additional patents as warranted [5]

Core Insights - Clearmind Medicine Inc. has commenced patient enrollment for its Phase I/IIa clinical trial of CMND-100 for Alcohol Use Disorder (AUD) at Tel Aviv Sourasky Medical Center, marking a significant milestone in the global study [1][2][4] - The trial aims to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100, a non-hallucinogenic, oral MEAI-based compound, with initial results indicating excellent safety and adherence [3][4] - Clearmind's intellectual property portfolio includes nineteen patent families with 31 granted patents, and the company plans to pursue additional patents to enhance its portfolio [5] Company Overview - Clearmind is a clinical-stage biotech company focused on developing novel neuroplastogen-derived therapeutics to address under-treated health issues, particularly AUD [1][4] - The company is committed to researching and commercializing psychedelic-based compounds as regulated medicines, foods, or supplements [4] Clinical Trial Details - The Phase I/IIa trial is being conducted at multiple prestigious sites, including Yale School of Medicine and Johns Hopkins University, in addition to TASMC [2] - The first completed cohort of the trial has shown no serious adverse events, indicating a positive safety profile for CMND-100 [3]